StockData
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc. (ALGS) stock

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.30−0.06 (-4.41%)

Close on Nov 18, 2026Market cap $16.24MP/E –Yield –

Aligos Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Aligos Therapeutics's free cash flow for the twelve months ending Mar 31, 2023 was -$81.78M. For fiscal 2024 it was -$80.87M. The highest annual figure on record is -$49.55M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$80.87M–
FY2023Dec 31, 2023-$79.02M–
FY2022Dec 31, 2022-$80.33M–
FY2021Dec 31, 2021-$116.55M–
FY2020Dec 31, 2020-$76.33M–
FY2019Dec 31, 2019-$49.55M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2023Mar 31, 2023-$22.39M–
Q4 FY2022Dec 31, 2022-$16.87M–
Q3 FY2022Sep 30, 2022-$17.14M–
Q2 FY2022Jun 30, 2022-$25.37M–
Q1 FY2022Mar 31, 2022-$20.95M–
Q4 FY2021Dec 31, 2021-$37.82M–
Q3 FY2021Sep 30, 2021-$25.47M–
Q2 FY2021Jun 30, 2021-$23.17M–
Q1 FY2021Mar 31, 2021-$30.10M–
Q4 FY2020Dec 31, 2020-$19.75M–
Q3 FY2020Sep 30, 2020-$16.91M–
Q2 FY2020Jun 30, 2020-$18.26M–
Q1 FY2020Mar 31, 2020-$21.41M–
Q4 FY2019Dec 31, 2019-$15.74M–

More Aligos Therapeutics figures

See a number that looks wrong?